96% cheaper, Avastin is just as effective as Eylea against eye disorder

A clinical trial has found that the oncology drug Avastin (bevacizumab) is about as effective as Eylea (aflibercept) in treating central retinal vein occlusion (CRVO), an eye condition.

For years, ophthalmologists have used Roche’s (ROG: SIX) bowel cancer drug Avastin off-label to treat macular degeneration, and related conditions, owing to its ability to prevent the blood vessel growth responsible for these disorders.

Data from the trial reveal that after six monthly injections, treatment with either drug improved visual acuity to the same extent on average.